Parkinson's disease: new treatments.
Parkinsonism is a movement disorder related to a central nervous system dopamine deficiency. L-dopa with or without carbidopa is presently the most effective medication. The use of this drug should be delayed as long as possible, and overtreatment should be avoided. Complications of long-term parkinsonism may respond in part to the direct dopamine receptor agonists. Physical therapy and emotional support for the patients and their families are an integral part of the management of the patient with Parkinson's disease.
D000109:Acetylcholine / Q000037:antagonists & inhibitors / Q000502:physiology; D000547:Amantadine / Q000627:therapeutic use; D001058:Apomorphine / Q000031:analogs & derivatives / Q000494:pharmacology; D001971:Bromocriptine / Q000494:pharmacology; D002230:Carbidopa / Q000009:adverse effects / Q000627:therapeutic use; D003376:Counseling; D004298:Dopamine / Q000502:physiology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors; D009461:Neurologic Manifestations; D010300:Parkinson Disease / Q000188:drug therapy* / Q000628:therapy; D026741:Physical Therapy Modalities; D011954:Receptors, Dopamine / Q000187:drug effects; D013788:Thalamus / Q000601:surgery
D008996:Monoamine Oxidase Inhibitors; D011954:Receptors, Dopamine; D001971:Bromocriptine; D007980:Levodopa; C009074:N-n-propylnorapomorphine; D000547:Amantadine; D002230:Carbidopa; D001058:Apomorphine; D000109:Acetylcholine; D004298:Dopamine